Skip to content

Beneficiaries

Digital migraine treatment

_DSC3882
Cerebri_prototype

Challenge

14.7% of the population is affected by migraine, the most common neurological disorder costing EU €50 billion annually. Migraine results in reduced quality of life and limited daily performance in work and social life. There is a pressing need for treatments without side-effects, that are affordable and more accessible than today’s alternatives, which mainly consist of medications associated with limited efficacy and significant side-effects.

Solution

CEREBRI is a digital treatment for preventing migraine, solving the demand for treatment without negative side-effects. With two wireless sensors and a smartphone app, patients can perform regular biofeedback training that has the potential to reduce migraine frequency by 50%. This enables treatment from the comfort of your own home, and virtual care from a physician, with potential cost savings of ~60% compared to biofeedback given in clinics. 

Achievements

Nordic Brain Tech, i3tex and Thorgate has made joint advancements in CEREBRI to optimize the treatment software and finger biosensor. The development has brought the product closer to TRL7 and enables verification and prototype manufacturing. 

Impacts

CEREBRI will have a significant impact on the preventive migraine market by providing patients with a more affordable and available treatment. CEREBRI can significantly increase a migraine patient’s quality of life, and reduce costs by 50% to sick leave for businesses and health care providers.

Partners

i3tex

https://www.i3tex.com

Italy

nordic brain tech

https://nordicbraintech.com/

Norway

Thorgate

https://thorgate.eu/

Estonia

Subscribe